Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$43.06|
|52 Week High||US$32.87|
|52 Week Low||US$65.25|
|1 Month Change||-2.95%|
|3 Month Change||-18.62%|
|1 Year Change||25.47%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||44.98%|
Recent News & Updates
|ACCD||US Healthcare||US Market|
Return vs Industry: ACCD underperformed the US Healthcare industry which returned 33.6% over the past year.
Return vs Market: ACCD underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: ACCD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ACCD's weekly volatility (6%) has been stable over the past year.
About the Company
Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services.
Accolade Fundamentals Summary
|ACCD fundamental statistics|
Is ACCD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACCD income statement (TTM)|
|Cost of Revenue||US$107.37m|
Last Reported Earnings
May 31, 2021
Next Earnings Date
Oct 07, 2021
|Earnings per share (EPS)||-1.29|
|Net Profit Margin||-44.02%|
How did ACCD perform over the long term?See historical performance and comparison
Is Accolade undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ACCD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ACCD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ACCD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: ACCD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ACCD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ACCD is overvalued based on its PB Ratio (6.5x) compared to the US Healthcare industry average (3.2x).
How is Accolade forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACCD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ACCD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ACCD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ACCD's revenue (29.9% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: ACCD's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACCD is forecast to be unprofitable in 3 years.
How has Accolade performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACCD is currently unprofitable.
Growing Profit Margin: ACCD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ACCD is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.
Accelerating Growth: Unable to compare ACCD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACCD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (32.2%).
Return on Equity
High ROE: ACCD has a negative Return on Equity (-19.54%), as it is currently unprofitable.
How is Accolade's financial position?
Financial Position Analysis
Short Term Liabilities: ACCD's short term assets ($453.5M) exceed its short term liabilities ($167.5M).
Long Term Liabilities: ACCD's short term assets ($453.5M) exceed its long term liabilities ($286.9M).
Debt to Equity History and Analysis
Debt Level: ACCD's debt to equity ratio (63.9%) is considered high.
Reducing Debt: Insufficient data to determine if ACCD's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACCD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ACCD has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.3% each year
What is Accolade current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ACCD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ACCD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ACCD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ACCD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ACCD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Raj Singh (53 yo)
Mr. Rajeev Singh, also known as Raj, serves as Director at Amperity, Inc. He has been the Chief Executive Officer and Executive Director of Accolade, Inc. since October 2015 and also serves as its Chairman...
CEO Compensation Analysis
Compensation vs Market: Raj's total compensation ($USD2.59M) is below average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Raj's compensation has been consistent with company performance over the past year.
Experienced Management: ACCD's management team is considered experienced (3.8 years average tenure).
Experienced Board: ACCD's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.2%.
Accolade, Inc.'s employee growth, exchange listings and data sources
- Name: Accolade, Inc.
- Ticker: ACCD
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$2.845b
- Shares outstanding: 66.07m
- Website: https://www.accolade.com
Number of Employees
- Accolade, Inc.
- 660 West Germantown Pike
- Suite 500
- Plymouth Meeting
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 22:01|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.